Summary
The stemness of different side population (SP) cell subtypes in ovarian cancer cells was studied, and the heterogeneity of ovarian cancer stem cells was analyzed. The cisplatin-resistant human serous ovarian cancer cell line C13 was stained with the bisbenzimide Hoechst 33342. A flow cytometry-based fluorescence-activated sorting method was used to obtain lower-SP (LSP) cells, upper-SP (USP) cells, and non-SP cells (NSP) based on their sensitivity to the staining time and Hoechst dye concentration. The sphere-forming capability, expression levels of stem cell markers, resistance to high concentrations of cisplatin, and subcutaneous tumorigenicity in NOD/SCID mice of the different cell subtypes were evaluated. The C13 cells contained SP cells with stemness characteristics, and the LSP cell subtype expressed higher levels of stem cell markers, had higher in vitro sphere-forming capability, higher cisplatin resistance and higher in vivo subcutaneous tumorigenesis than USP cells (P<0.05). NSP cells had no stemness. In conclusion, different subtypes of ovarian cancer SP cells have different stemness levels, and ovarian cancer stem cells may be heterogeneous.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Prager BC, Xie Q, Bao S. Cancer Stem Cells: The Architects of the Tumor Ecosystem. Cell Stem Cell, 2019,24(1):41–53
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008,8(10):755–768
rasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer, 2017, 16(1):41
von Furstenberg RJ, Buczacki SJ, Smith BJ, et al. Side population sorting separates subfractions of cycling and non-cycling intestinal stem cells. Stem Cell Res, 2014,12(2):364–375
Eun K, Ham SW, Kim H, et al. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Reports, 2017,50(3):117–125
Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res, 2008,68(11):4311–4320
Curley MD, Therrien VA, Cummings CL, et al. CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer. Stem Cells, 2009,27(12):2875–2883
Shi MF, Jiao J, Lu WG, et al. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci, 2010,67(22):3915–3925
Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle, 2009,8(1):158–166
Chen WC, Hsu HP, Li CY, et al. Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. Int J Oncol, 2016,49(5):1881–1889
Liu TJ, Sun BC, Zhao XL, et al. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene, 2013,32(5):544–553
Brabletz T, Jung A, Spaderna S, et al. Opinion: migrating cancer stem cells — an integrated concept of malignant tumour progression. Nat Rev Cancer, 2005,5(9):744–749
Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med, 1996,183(4): 1797–1806
Challen GA, Boles NC, Chambers SM, et al. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell, 2010,6(3):265–278
Saygin C, Matei D, Majeti R, et al. Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell, 2019,24(1):25–40
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by the Fundamental Research Funds for the Central Universities (HUST: No. 2017KFYXJJ122) and a grant from the National Natural Science Foundation of China (No. 81672580).
Conflict of Interest Statement
The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.
Rights and permissions
About this article
Cite this article
Weng, Yj., Zhang, Xx., Wu, X. et al. Distinct Side Population Cell Subtypes Have Different Stemness Levels in Human Ovarian Cancer Cells. CURR MED SCI 41, 127–132 (2021). https://doi.org/10.1007/s11596-021-2327-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2327-0